The Prevalence of Prostate Cancer in Organ Donors With Increased Prostate-Specific Antigen

被引:0
|
作者
Bzoma, Beata [1 ]
Debska-Slizien, Alicja [1 ]
Roscinska, Paulina [2 ]
Piatkowski, Konrad [2 ]
Kostro, Justyna [2 ]
Lukianski, Marian [2 ]
Bigda, Justyna [2 ]
Chamienia, Andrzej [3 ]
机构
[1] Dept Nephrol Transplantol & Internal Dis, Poznan, Poland
[2] Div Gen Endocrine & Transplant Surg, Gdansk, Poland
[3] Gdansk Med Univ, Reg Transplant List, Gdansk, Poland
关键词
D O I
10.1016/j.transproceed.2024.03.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Elevated prostate-specific antigen (PSA) levels were found in 139 of 472 kidney donors from our transplant center tested between 2009 and 2022, representing 29%. The mean age of these donors was 47.3 years. PSA values ranged from 2.8 to 160.4 ng/mL (mean 13.9 ng/mL). The recommended range is <2.5 ng/mL. Prostate histopathologic examination was performed in 38 of the 139 (27%). We found 14 cases of prostate cancer (PCa), with Gleason 3+3 in 8 cases, 3+4 in 4 cases (one donor disqualification), 1 case Gleason 4+3 (donor disqualification), and 1 case Gleason 4+5 (donor disqualification). Thirty-three patients met the criteria, were aged >= 50 years, and had a PSA level >10 mg/mL. Of these, prostate histopathologic examination was performed in 24 cases. PCa was found in 10 cases (42%). There was no difference between donors >= 50 years of age, with PSA>10 ng/mL with and without pathomorphologic diagnosis of PCa regarding age (mean 60.4 vs 60.6 years), creatinine clearance according to the Cockroft-Gaulta formula (mean 101.6 vs 94.8 mL/min) and PSA levels (mean 34.1 vs 29.3 ng/mL). Among other donors with PCa, 3 were <50 years with PSA >10 ng/mL, and 1 was >= 50 years with PSA<8 ng/mL. Kidneys from donors with PCa were transplanted into 10 men and 9 women. Follow-up time was 1 to 10 years. No cases of PCa transmission were reported. One of the recipients died of neoplasm-breast cancer. Donors >= 50 years of age with PSA>10 ng/mL have a higher risk for Pca. Accepting donors with Pca (Gleason 3+3 and 3+4) possesses minimal risk for transmission. All donors >= 50 years with increased PSA require further diagnostic procedures (eg, digital rectal examination, ultrasound, and eventually histologic examination).
引用
收藏
页码:763 / 766
页数:4
相关论文
共 50 条
  • [31] Biomarkers for prostate cancer: prostate-specific antigen and beyond
    Duffy, Michael J.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (03) : 326 - 339
  • [32] PROSTATE-SPECIFIC ANTIGEN IN SCREENING FOR PROSTATE-CANCER
    MAYER, FJ
    CRAWFORD, ED
    WESTERN JOURNAL OF MEDICINE, 1994, 160 (02): : 168 - 168
  • [33] Prostate-specific Antigen Testing and Prostate Cancer Screening
    Djavan, Bob
    Eckersberger, Elisabeth
    Finkelstein, Julia
    Sadri, Helen
    Taneja, Samir S.
    Lepor, Herbert
    PRIMARY CARE, 2010, 37 (03): : 441 - +
  • [34] The Role of Prostate-Specific Antigen in Prostate Cancer Screening
    Constantin, Traian Vasile
    Madan, Victor Lucian
    Constantin, Maria-Magdalena
    Morariu, Silviu-Horia
    Braticevici, Bogdan
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2014, 22 (02): : 275 - 281
  • [35] The case for prostate cancer screening with prostate-specific antigen
    Andriole, Gerald
    Djavan, Bob
    Fleshner, Neil
    Schroder, Fritz
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (12) : 737 - 745
  • [36] PROSTATE-SPECIFIC ANTIGEN IN SCREENING OF PROSTATE-CANCER
    CHU, TM
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1994, 8 (05) : 323 - 326
  • [37] Prostate-specific antigen in the early detection of prostate cancer
    Thompson, Ian M.
    Ankerst, Donna P.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 176 (13) : 1853 - 1858
  • [38] Determination of prostate-specific antigen in the diagnosis of prostate cancer
    Semjonow, A
    FORTSCHRITTE IN DIAGNOSTIK UND THERAPIE DES PROSTATAKARZINOMS, 1997, 5 : 9 - 16
  • [39] Prostate-Specific Antigen, Prostate Cancer, and Disorders of Hemostasis
    Lippi, Giuseppe
    Plebani, Mario
    Franchini, Massimo
    Guidi, Gian Cesare
    Favaloro, Emmanuel J.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2009, 35 (07): : 654 - 664
  • [40] Impact of prostate-specific antigen screening on prostate cancer
    Zincke, H
    UROLOGY, 1996, 47 (05) : 783 - 783